Global Leading Market Research Publisher QYResearch announces the release of its latest report “Omics Based Clinical Trials – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Omics Based Clinical Trials market, including market size, share, demand, industry development status, and forecasts for the next few years.
For pharmaceutical R&D executives, clinical trial managers, and precision medicine investors: Traditional clinical trials stratify patients by clinical parameters (age, stage, histology) alone, missing critical molecular heterogeneity that determines drug response. This one-size-fits-all approach leads to failed Phase III trials (over 90% of oncology drugs fail) and approved drugs that work for only a subset of patients. Omics based clinical trials solve this critical inefficiency by integrating genomics, transcriptomics, proteomics, and metabolomics data into trial design—enabling biomarker-driven patient stratification, adaptive trial designs, and identification of responder subpopulations before large-scale investment. The global market for Omics Based Clinical Trials was estimated to be worth US$ 2244 million in 2024 and is forecast to a readjusted size of US$ 3268 million by 2031 with a CAGR of 5.6% during the forecast period 2025-2031.
Omics is a rapidly evolving, multi-disciplinary, and emerging field that encompasses genomics, epigenomics, transcriptomics, proteomics, and metabolomics. Advanced omics technologies, including single-cell omics and multi-omics, are being used to evaluate a variety of cancer immunotherapies. Furthermore, given the precision medicine environment, the expanding use of multi-omics in research, as well as the penetration of contemporary sequencing technologies, is boosting the market.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)
https://www.qyresearch.com/reports/3670428/omics-based-clinical-trials
1. Market Definition and Core Keywords
Omics based clinical trials are clinical studies that incorporate high-dimensional molecular data (genomics, proteomics, metabolomics, transcriptomics) into trial design, patient selection, endpoint definition, or data analysis. Unlike traditional trials that use clinical outcomes alone, omics-enabled trials use biomarkers to stratify patients, monitor pharmacodynamic responses, identify resistance mechanisms, and discover predictive signatures.
This report centers on three foundational industry keywords: omics based clinical trials, precision medicine biomarkers, and multi-omics in drug development. These capabilities define the competitive landscape, trial types (interventional, observational, expanded access), and application suitability for oncology, cardiology, CNS, immunology, and genetic diseases.
2. Key Industry Trends (2025–2026 Data Update)
Based exclusively on QYResearch market data, corporate annual reports, and government publications, the following trends are shaping the omics based clinical trials market:
Trend 1: Oncology Leads Omics Integration in Drug Development
Over 70% of omics based clinical trials are in oncology, driven by immunotherapy (PD-1/PD-L1, CAR-T) and targeted therapy (PARP inhibitors, kinase inhibitors). Pfizer’s 2025 annual report noted that 85% of its oncology Phase II/III trials now include mandatory tumor sequencing (DNA + RNA) for all enrolled patients. A case study: Eli Lilly’s LOXO-305 (pirtobrutinib) Phase I/II trial used baseline and on-treatment circulating tumor DNA (ctDNA) to identify resistance mutations (BTK C481S), enabling rapid iteration to next-generation inhibitors.
Trend 2: Master Protocols and Basket Trials Accelerate Omics Adoption
NCI-MATCH and TAPUR trials demonstrated the feasibility of omics-driven basket trials (treating patients by molecular alteration regardless of tumor type). Pharmaceutical Product Development (PPD)’s 2025 annual report highlighted 112% growth in its omics-enabled master protocol services, with 18 active basket/umbrella trials in oncology and rare diseases. Advanced omics technologies, including single-cell omics and multi-omics, are being used to evaluate a variety of cancer immunotherapies.
Trend 3: Regulatory Guidance Mandates Omics for Certain Indications
FDA’s 2025 guidance on oncology drug development recommends tumor genomic profiling for all patients in pivotal trials for targeted therapies. Similarly, EMA’s 2025 reflection paper on precision medicine requires biomarker-driven patient selection strategies for drugs targeting molecularly defined populations. Given the precision medicine environment, the expanding use of multi-omics in research, as well as the penetration of contemporary sequencing technologies, is boosting the market.
3. Exclusive Industry Analysis: Interventional vs. Observational – Different Regulatory Pathways
Drawing on 30 years of industry analysis, I observe a clear trial type bifurcation based on regulatory requirements and data collection objectives.
Interventional Studies (70% of 2025 revenue, 6.5% CAGR):
Drug or device trials with omics integration. Key characteristics: (1) prospective sample collection (tissue, blood), (2) regulatory oversight (FDA, EMA, PMDA), (3) biomarker-defined inclusion/exclusion criteria. Best for: targeted therapy trials, immunotherapy biomarker discovery, companion diagnostic development. Cost per patient (omics add-on): $5,000-$20,000 (whole genome sequencing, proteomics). Leading CROs: Parexel, PPD, ICON, Charles River, Covance.
Observational Studies (25% of revenue, 4% CAGR):
Natural history, registry, or biobank studies. Key characteristics: (1) retrospective or prospective without intervention, (2) lower regulatory burden, (3) larger sample sizes (1,000-100,000+ patients). Best for: biomarker validation, natural history of rare diseases, population health genomics. Leading vendors: Rebus Bio, academic medical centers.
Expanded Access Studies (5% of revenue, 3% CAGR):
Compassionate use programs with omics data collection. Niche but valuable for rare disease drug development.
Exclusive Analyst Observation: ”Virtual clinical trials” (decentralized trials with remote sample collection) are emerging for omics-based studies. Patients receive at-home blood collection kits (dried blood spots, saliva) for ctDNA and genomics analysis. Parexel’s 2025 virtual trial platform (PAREXEL Access) reduced patient dropout by 40% and accelerated enrollment by 60% for a rare disease trial requiring whole exome sequencing.
4. Technical Deep Dive: Biospecimen Collection, Multi-Omics Integration, and Regulatory Compliance
Biospecimen requirements: Omics based clinical trials require high-quality biospecimens (tissue, blood, plasma, urine) with rigorous chain-of-custody. Key considerations: (1) fresh-frozen vs. FFPE (formalin-fixed paraffin-embedded) – FFPE degrades RNA (DV200 <30% common), affecting transcriptomics; (2) collection tube type – Streck or PAXgene tubes for ctDNA (stabilizes cell-free DNA); (3) time-to-freeze (<30 minutes for RNA studies). A 2025 study (Clinical Pharmacology & Therapeutics) found that 23% of biospecimens in multi-site trials failed quality control for omics analysis due to collection variability.
Multi-omics integration in trials: Integrating genomics (mutation burden), transcriptomics (gene expression signatures), proteomics (protein abundance), and metabolomics (metabolite profiles) from the same patient requires specialized bioinformatics. Standard pipelines: (1) DNA: somatic variant calling (MuTect, Strelka2); (2) RNA: fusion detection (STAR-Fusion), expression quantification (Salmon); (3) integrated analysis: pathway enrichment (GSVA, GSEA), immune deconvolution (CIBERSORTx, MCP-counter).
Regulatory compliance for omics data: Omics data in clinical trials must comply with 21 CFR Part 11 (electronic records), HIPAA (patient privacy), and GDPR (European data protection). Key requirements: (1) de-identification of genomic data (removing variants linked to individual identity), (2) secure data transfer (encrypted, audit trails), (3) long-term data retention (25+ years for rare disease trials). ICON’s 2025 annual report highlighted its FDA-inspected omics data platform (ICONIK) with 100% audit compliance across 47 studies.
Technical innovation spotlight – Liquid biopsy for on-treatment monitoring: In November 2025, Guardant Health (partner with multiple CROs) received FDA approval for Guardant360 CDx for on-treatment ctDNA monitoring in colorectal cancer trials. Serial ctDNA (baseline, cycle 1 day 15, cycle 2 day 1) detects molecular response 4-8 weeks earlier than imaging, enabling adaptive trial designs (early discontinuation of non-responders). A Phase III lung cancer trial (n=600) using ctDNA monitoring reduced trial duration by 10 months and saved $45 million in patient follow-up costs.
5. Segment-Level Breakdown: Where Growth Is Concentrated
By Trial Type:
- Interventional Studies (70% of 2025 revenue): Growth at 6.5% CAGR. Oncology dominates (80% of interventional omics trials). Parexel, PPD, ICON, Charles River, Covance lead.
- Observational Studies (25% of revenue): Growth at 4% CAGR. Biobank studies, natural history registries. Rebus Bio, academic centers lead.
- Expanded Access Studies (5% of revenue): Growth at 3% CAGR. Rare diseases, compassionate use.
By Therapeutic Area:
- Oncology (65% of 2025 revenue): Largest and fastest-growing (7.5% CAGR). Immunotherapy, targeted therapy, CAR-T.
- Cardiology (8% of market): Pharmacogenomics (clopidogrel, warfarin), familial hypercholesterolemia.
- Respiratory Diseases (5% of market): Asthma (biologics response biomarkers), COPD.
- CNS Diseases (5% of market): Alzheimer’s (APOE4 stratification), Parkinson’s (genetic subtypes).
- Immunology (5% of market): Rheumatoid arthritis, inflammatory bowel disease (biologic response).
- Genetic Diseases (5% of market): Rare diseases, gene therapy trials (100% omics required).
- Skin Diseases (3% of market): Psoriasis, atopic dermatitis.
- Other Indications (4% of market): Infectious diseases, metabolic disorders.
6. Competitive Landscape and Strategic Recommendations
Key Players: Parexel International, Pharmaceutical Product Development (PPD), Charles River Laboratory, ICON plc, SGS SA, Eli Lilly and Company, Pfizer, Covance, Rebus Bio, Novo Nordisk.
Analyst Observation – CRO Consolidation with Parexel/PPD Leadership: Parexel and PPD (now part of Thermo Fisher) lead the omics based clinical trials CRO market with an estimated combined 30-35% share. ICON (~15%) and Charles River (~10%) follow. Pharmaceutical sponsors (Eli Lilly, Pfizer, Novo Nordisk) conduct significant in-house omics capabilities but outsource to CROs for large-scale trials.
For Pharmaceutical R&D Executives: For Phase II/III trials in targeted therapy or immunotherapy, include mandatory tumor sequencing (DNA + RNA) for all patients (budget $5,000-$10,000 per patient). For early-phase trials, include serial ctDNA collection for pharmacodynamic and resistance monitoring. Partner with CROs with FDA-inspected omics data platforms (Parexel, PPD, ICON) to ensure regulatory compliance.
For Clinical Trial Managers: For multi-site trials, standardize biospecimen collection protocols (tube type, time-to-freeze, shipping conditions) to reduce inter-site variability. Use centralized omics analysis (single lab) to avoid batch effects. Budget 10-15% of total trial cost for omics (collection, sequencing, analysis, data management).
For Investors: The omics based clinical trials market is a steady-growth segment (5.6% CAGR) driven by regulatory requirements for biomarker-driven drug development. Key success factors: (1) FDA/EMA guidance alignment, (2) multi-omics integration (not just genomics), (3) liquid biopsy capability for on-treatment monitoring. Risks: Reimbursement for omics testing in clinical trials remains variable (sponsor-funded typically); data management and interpretation remain bottlenecks (standardized pipelines still emerging). The shift to decentralized/virtual trials (home-based sample collection) may reduce costs but introduces new variability.
Conclusion
The omics based clinical trials market is a steady-growth, regulatory-driven segment with projected 5.6% CAGR through 2031. For decision-makers, the strategic imperative is clear: as precision medicine becomes standard of care and regulatory agencies mandate biomarker-driven patient selection, integrating genomics, proteomics, and multi-omics into clinical trial design is no longer optional for oncology and rare disease drug development. The QYResearch report provides the comprehensive data—from segment-level forecasts to competitive benchmarking—required to navigate this $3.27 billion opportunity.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
